| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV-1 | 28 | 2019 | 3365 | 1.49 | Why? |
| HIV Integrase Inhibitors | 6 | 2019 | 173 | 1.22 | Why? |
| Sarcoma, Kaposi | 5 | 2020 | 97 | 1.21 | Why? |
| Drug Resistance, Viral | 17 | 2019 | 1083 | 1.15 | Why? |
| Herpesvirus 8, Human | 5 | 2020 | 97 | 1.11 | Why? |
| Viral Load | 26 | 2021 | 15850 | 1.05 | Why? |
| HIV Infections | 33 | 2020 | 11620 | 1.04 | Why? |
| Anti-HIV Agents | 12 | 2019 | 2209 | 0.81 | Why? |
| Drug Resistance, Multiple, Viral | 1 | 2019 | 37 | 0.79 | Why? |
| HIV | 3 | 2020 | 1116 | 0.76 | Why? |
| Raltegravir Potassium | 4 | 2019 | 132 | 0.68 | Why? |
| Herpesviridae Infections | 1 | 2018 | 172 | 0.62 | Why? |
| Antiretroviral Therapy, Highly Active | 6 | 2019 | 952 | 0.60 | Why? |
| HIV Integrase | 4 | 2018 | 67 | 0.56 | Why? |
| Hepacivirus | 4 | 2019 | 1509 | 0.56 | Why? |
| Pyridazines | 3 | 2019 | 86 | 0.53 | Why? |
| Proviruses | 1 | 2013 | 82 | 0.52 | Why? |
| Viremia | 4 | 2020 | 1020 | 0.49 | Why? |
| HIV Protease Inhibitors | 4 | 2019 | 434 | 0.47 | Why? |
| HIV Protease | 4 | 2019 | 86 | 0.45 | Why? |
| DNA, Viral | 3 | 2019 | 2521 | 0.43 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.40 | Why? |
| Lymphoma, Primary Effusion | 2 | 2018 | 11 | 0.37 | Why? |
| Castleman Disease | 2 | 2018 | 28 | 0.35 | Why? |
| HIV Envelope Protein gp41 | 3 | 2019 | 153 | 0.34 | Why? |
| Darunavir | 3 | 2018 | 477 | 0.31 | Why? |
| Molecular Diagnostic Techniques | 2 | 2020 | 4239 | 0.28 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2018 | 275 | 0.28 | Why? |
| Treatment Failure | 6 | 2019 | 2106 | 0.27 | Why? |
| High-Throughput Nucleotide Sequencing | 7 | 2019 | 3633 | 0.26 | Why? |
| Genotype | 7 | 2019 | 4697 | 0.26 | Why? |
| Mutation, Missense | 3 | 2018 | 863 | 0.26 | Why? |
| Hepatitis C | 3 | 2019 | 1514 | 0.25 | Why? |
| Mutation | 10 | 2021 | 12376 | 0.25 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 95 | 0.23 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 39 | 0.23 | Why? |
| HIV Reverse Transcriptase | 2 | 2018 | 104 | 0.23 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.21 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2019 | 309 | 0.21 | Why? |
| HIV Seropositivity | 2 | 2019 | 320 | 0.20 | Why? |
| Lung Diseases, Fungal | 1 | 2021 | 167 | 0.20 | Why? |
| Paris | 5 | 2021 | 1287 | 0.19 | Why? |
| Lamivudine | 2 | 2018 | 210 | 0.19 | Why? |
| Quasispecies | 1 | 2020 | 108 | 0.19 | Why? |
| HIV Antibodies | 2 | 2017 | 776 | 0.19 | Why? |
| Polymerization | 1 | 2018 | 46 | 0.18 | Why? |
| beta-Cyclodextrins | 1 | 2018 | 87 | 0.18 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.18 | Why? |
| Amino Acid Substitution | 3 | 2021 | 1706 | 0.18 | Why? |
| Antibodies, Neutralizing | 4 | 2021 | 25288 | 0.18 | Why? |
| Intestinal Neoplasms | 1 | 2017 | 42 | 0.17 | Why? |
| Dideoxynucleosides | 1 | 2017 | 92 | 0.17 | Why? |
| Invasive Fungal Infections | 1 | 2021 | 274 | 0.16 | Why? |
| Molecular Epidemiology | 2 | 2019 | 1638 | 0.16 | Why? |
| Neuromyelitis Optica | 1 | 2021 | 397 | 0.15 | Why? |
| CD4 Lymphocyte Count | 5 | 2019 | 1517 | 0.15 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.15 | Why? |
| Antibodies, Antiphospholipid | 1 | 2020 | 519 | 0.15 | Why? |
| Cerebrospinal Fluid | 1 | 2017 | 234 | 0.15 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.15 | Why? |
| Atazanavir Sulfate | 1 | 2018 | 213 | 0.15 | Why? |
| Lymphoma | 1 | 2021 | 522 | 0.15 | Why? |
| RNA, Small Interfering | 2 | 2018 | 817 | 0.15 | Why? |
| Urogenital Neoplasms | 1 | 2017 | 177 | 0.14 | Why? |
| Pulmonary Aspergillosis | 1 | 2020 | 408 | 0.14 | Why? |
| Natural Killer T-Cells | 1 | 2016 | 191 | 0.14 | Why? |
| B-Lymphocyte Subsets | 1 | 2016 | 372 | 0.14 | Why? |
| Middle Aged | 32 | 2021 | 270681 | 0.14 | Why? |
| Humans | 66 | 2021 | 930598 | 0.14 | Why? |
| Male | 39 | 2021 | 367725 | 0.13 | Why? |
| Receptors, Virus | 2 | 2021 | 5659 | 0.13 | Why? |
| Skin Neoplasms | 2 | 2017 | 1679 | 0.13 | Why? |
| Adult | 29 | 2021 | 244371 | 0.13 | Why? |
| Cluster Analysis | 2 | 2019 | 3001 | 0.13 | Why? |
| Binding Sites | 3 | 2021 | 6201 | 0.13 | Why? |
| Protein Interaction Domains and Motifs | 1 | 2021 | 2134 | 0.13 | Why? |
| Semen | 1 | 2019 | 550 | 0.13 | Why? |
| Sequence Analysis, DNA | 2 | 2019 | 2830 | 0.13 | Why? |
| Hepatitis E | 1 | 2018 | 319 | 0.13 | Why? |
| Sofosbuvir | 1 | 2018 | 518 | 0.12 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.12 | Why? |
| Sexual and Gender Minorities | 2 | 2019 | 1019 | 0.12 | Why? |
| Recombination, Genetic | 1 | 2019 | 1265 | 0.12 | Why? |
| DNA | 1 | 2018 | 778 | 0.12 | Why? |
| France | 8 | 2021 | 12074 | 0.12 | Why? |
| Cell Line, Tumor | 1 | 2021 | 3608 | 0.12 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2021 | 13720 | 0.11 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.11 | Why? |
| Female | 31 | 2021 | 380317 | 0.11 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.11 | Why? |
| Ritonavir | 4 | 2020 | 4212 | 0.11 | Why? |
| Cyclohexanes | 1 | 2010 | 43 | 0.11 | Why? |
| Immunologic Factors | 2 | 2017 | 4206 | 0.11 | Why? |
| Sexually Transmitted Diseases | 1 | 2019 | 694 | 0.11 | Why? |
| Ribavirin | 1 | 2018 | 1182 | 0.10 | Why? |
| Phylogeny | 5 | 2020 | 13341 | 0.10 | Why? |
| Heart Transplantation | 2 | 2018 | 1293 | 0.10 | Why? |
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 30 | 0.10 | Why? |
| Protein Binding | 3 | 2021 | 11430 | 0.10 | Why? |
| Nitriles | 3 | 2019 | 1053 | 0.10 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.10 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.09 | Why? |
| Lentivirus | 1 | 2009 | 310 | 0.09 | Why? |
| Neoplasms | 3 | 2021 | 17251 | 0.09 | Why? |
| CD4-Positive T-Lymphocytes | 3 | 2013 | 4545 | 0.09 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.09 | Why? |
| RNA, Viral | 5 | 2021 | 32276 | 0.09 | Why? |
| Plasma | 1 | 2017 | 1809 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.08 | Why? |
| Pyrimidines | 3 | 2019 | 1557 | 0.08 | Why? |
| Triazoles | 1 | 2010 | 440 | 0.08 | Why? |
| Oxazines | 2 | 2018 | 279 | 0.08 | Why? |
| Homosexuality, Male | 3 | 2019 | 1158 | 0.08 | Why? |
| Computer Simulation | 1 | 2021 | 4982 | 0.08 | Why? |
| Disease Transmission, Infectious | 2 | 2019 | 9044 | 0.07 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.07 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.07 | Why? |
| Multiple Sclerosis | 1 | 2021 | 2600 | 0.07 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.07 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.07 | Why? |
| Piperazines | 2 | 2018 | 445 | 0.07 | Why? |
| Genotyping Techniques | 2 | 2017 | 360 | 0.07 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.07 | Why? |
| Leukocytes, Mononuclear | 1 | 2013 | 2115 | 0.07 | Why? |
| Coinfection | 2 | 2020 | 6820 | 0.06 | Why? |
| Lung Neoplasms | 2 | 2017 | 3228 | 0.06 | Why? |
| Gene Frequency | 2 | 2018 | 1210 | 0.06 | Why? |
| Aged | 14 | 2021 | 215776 | 0.06 | Why? |
| Virus Diseases | 1 | 2020 | 3779 | 0.06 | Why? |
| Sequence Alignment | 2 | 2019 | 2109 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Pyridones | 2 | 2018 | 738 | 0.06 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.06 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.06 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.05 | Why? |
| Virus Replication | 2 | 2021 | 14331 | 0.05 | Why? |
| Lip | 1 | 2020 | 61 | 0.05 | Why? |
| Viral Nonstructural Proteins | 1 | 2018 | 4810 | 0.05 | Why? |
| Reagent Kits, Diagnostic | 2 | 2021 | 2149 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.05 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.05 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.05 | Why? |
| Prospective Studies | 6 | 2020 | 43301 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.05 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.05 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.05 | Why? |
| Contact Tracing | 1 | 2019 | 8448 | 0.05 | Why? |
| Microbial Sensitivity Tests | 2 | 2018 | 2886 | 0.05 | Why? |
| Immunocompetence | 1 | 2020 | 280 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.05 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Emtricitabine | 1 | 2018 | 202 | 0.04 | Why? |
| Retinal Vasculitis | 1 | 2017 | 33 | 0.04 | Why? |
| Mali | 1 | 2017 | 181 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Antigens, CD1d | 1 | 2016 | 12 | 0.04 | Why? |
| Lymphedema | 1 | 2017 | 44 | 0.04 | Why? |
| Immunoglobulin D | 1 | 2016 | 24 | 0.04 | Why? |
| Microscopy, Fluorescence | 1 | 2018 | 335 | 0.04 | Why? |
| Influenza, Human | 2 | 2020 | 10779 | 0.04 | Why? |
| Radiotherapy, Adjuvant | 1 | 2017 | 180 | 0.04 | Why? |
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2016 | 58 | 0.04 | Why? |
| Compassionate Use Trials | 1 | 2021 | 632 | 0.04 | Why? |
| Leg | 1 | 2017 | 142 | 0.04 | Why? |
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 382 | 0.04 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.04 | Why? |
| Luciferases | 1 | 2018 | 378 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.04 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 2984 | 0.04 | Why? |
| Cell Proliferation | 2 | 2016 | 1973 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2017 | 582 | 0.04 | Why? |
| Markov Chains | 1 | 2017 | 502 | 0.04 | Why? |
| Phylogeography | 1 | 2019 | 824 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Transfection | 1 | 2018 | 864 | 0.04 | Why? |
| Central Nervous System | 1 | 2021 | 701 | 0.04 | Why? |
| Amputation | 1 | 2017 | 331 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Cardiomyopathy, Dilated | 1 | 2018 | 251 | 0.04 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.03 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Quality-Adjusted Life Years | 1 | 2017 | 511 | 0.03 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2018 | 657 | 0.03 | Why? |
| Influenza Vaccines | 1 | 2010 | 2941 | 0.03 | Why? |
| Protein Structure, Tertiary | 1 | 2018 | 1565 | 0.03 | Why? |
| Hepatitis E virus | 1 | 2018 | 306 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| General Practitioners | 1 | 2020 | 568 | 0.03 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Neoplasm Recurrence, Local | 1 | 2020 | 1063 | 0.03 | Why? |
| Molecular Docking Simulation | 2 | 2018 | 6902 | 0.03 | Why? |
| Spleen | 1 | 2016 | 877 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Virulence | 1 | 2019 | 2172 | 0.03 | Why? |
| Mutant Proteins | 1 | 2013 | 328 | 0.03 | Why? |
| Drug Interactions | 1 | 2019 | 1653 | 0.03 | Why? |
| Viral Proteins | 2 | 2020 | 7370 | 0.03 | Why? |
| Gene Expression Regulation, Viral | 1 | 2017 | 925 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Macrophage Inflammatory Proteins | 1 | 2009 | 14 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.03 | Why? |
| Small Molecule Libraries | 1 | 2018 | 1060 | 0.02 | Why? |
| Disease Outbreaks | 4 | 2020 | 27595 | 0.02 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Switzerland | 1 | 2017 | 2738 | 0.02 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.02 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2019 | 3239 | 0.02 | Why? |
| Protein Conformation | 1 | 2019 | 4386 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2019 | 6049 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.02 | Why? |
| Graft Rejection | 1 | 2017 | 1766 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2021 | 4418 | 0.02 | Why? |
| Adolescent | 4 | 2020 | 86841 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2021 | 3099 | 0.02 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.02 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.02 | Why? |
| Infant | 2 | 2020 | 30274 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Fatigue | 1 | 2017 | 2479 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2017 | 4758 | 0.02 | Why? |
| Models, Molecular | 1 | 2019 | 7616 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2018 | 3388 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.02 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Killer Cells, Natural | 1 | 2013 | 2093 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2013 | 5814 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Lymphocyte Activation | 1 | 2009 | 2742 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Immunologic Memory | 1 | 2009 | 3362 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Biomarkers | 1 | 2019 | 23361 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.01 | Why? |
| Cell Line | 1 | 2009 | 12040 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2010 | 5837 | 0.01 | Why? |
| Mice | 1 | 2013 | 21357 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Animals | 1 | 2013 | 78931 | 0.00 | Why? |